Home » Stocks » CLRB

Cellectar BioSciences, Inc. (CLRB)

Stock Price: $1.91 USD 0.05 (2.69%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
Pre-market: $1.90 -0.01 (-0.52%) Mar 2, 5:22 AM
Market Cap 86.30M
Revenue (ttm) n/a
Net Income (ttm) -14.86M
Shares Out 26.33M
EPS (ttm) -1.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $1.91
Previous Close $1.86
Change ($) 0.05
Change (%) 2.69%
Day's Open 1.96
Day's Range 1.88 - 1.98
Day's Volume 933,557
52-Week Range 1.01 - 2.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

FLORHAM PARK, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and com...

GlobeNewsWire - 1 month ago

Benefits include 10 years of market exclusivity in the European Union Benefits include 10 years of market exclusivity in the European Union

GlobeNewsWire - 2 months ago

FLORHAM PARK, N.J., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and comm...

GlobeNewsWire - 2 months ago

FLORHAM PARK, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and comm...

GlobeNewsWire - 2 months ago

FLORHAM PARK, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and comm...

Insider Monkey - 3 months ago

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. A...

GlobeNewsWire - 3 months ago

FLORHAM PARK, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and comm...

Zacks Investment Research - 5 months ago

The dollar has not only strengthened in recent times but it seems there is even more room for growth. So, let's find out which stocks stand to benefit from dollar's comeback.

Other stocks mentioned: APEI, AQMS, BZH
Seeking Alpha - 5 months ago

Cellectar Biosciences Phase 2 Data In Multiple Myeloma Is Worth A Look

GlobeNewsWire - 5 months ago

40% overall response rate (ORR) with a total administered dose of 60 mCi or greater 40% overall response rate (ORR) with a total administered dose of 60 mCi or greater

Zacks Investment Research - 6 months ago

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: AWR, CVEO, KIN, POR
GlobeNewsWire - 6 months ago

Poster highlights the Phase 2a study data in relapsed or refractory lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s macroglobulinemia (WM)

GlobeNewsWire - 6 months ago

FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commerc...

Zacks Investment Research - 7 months ago

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: ACRX, BDSI, BNFT, LNT
GlobeNewsWire - 7 months ago

Data highlight initial results of 100% overall response rate from ongoing Phase 2 trial in Relapsed or Refractory lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s Macroglobulinemia (WM) Data hig...

Benzinga - 8 months ago

Cellectar Biosciences (NASDAQ: CLRB) shares are trading higher on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating and $5 price target.

GlobeNewsWire - 8 months ago

FLORHAM PARK, N.J., July 01, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commerc...

GlobeNewsWire - 8 months ago

Covers composition of matter and method of use into 2036 for proprietary PLE analogs in combination with various small molecule chemotherapeutics Covers composition of matter and method of use...

GlobeNewsWire - 8 months ago

FLORHAM PARK, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercializa...

GlobeNewsWire - 8 months ago

FLORHAM PARK, N.J., June 03, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commerc...

GlobeNewsWire - 9 months ago

Designation Comes with Financial and Scientific Incentives Designation Comes with Financial and Scientific Incentives

GlobeNewsWire - 9 months ago

FLORHAM PARK, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci...

GlobeNewsWire - 9 months ago

Patent covers the phospholipid ether (PLE) delivery vehicle combined with I-131 and I-125 Patent covers the phospholipid ether (PLE) delivery vehicle combined with I-131 and I-125

GlobeNewsWire - 1 year ago

FLORHAM PARK, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commerc...

GlobeNewsWire - 1 year ago

FLORHAM PARK, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commerc...

GlobeNewsWire - 1 year ago

30% overall response rate seen with an average progression free survival of 4.5 months and an acceptable and expected safety profile

GlobeNewsWire - 1 year ago

FLORHAM PARK, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commerc...

GlobeNewsWire - 1 year ago

FLORHAM PARK, N.J., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commerc...

GlobeNewsWire - 1 year ago

Data showed durable clinical responses, including a 33% overall response rate (ORR) and 16.6% complete response (CR) Data showed durable clinical responses, including a 33% overall response ra...

GlobeNewsWire - 1 year ago

FLORHAM PARK, N.J., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commer...

GlobeNewsWire - 1 year ago

Data presented at the 17th International Myeloma Workshop

GlobeNewsWire - 1 year ago

FLORHAM PARK, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commer...

Benzinga - 1 year ago

The biotechnology space is an exciting one with incredible potential for investors.

Other stocks mentioned: AMRN, BMRN, GWPH, SNY

About CLRB

Cellectar Biosciences, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PD... [Read more...]

Industry
Biotechnology
Founded
2002
CEO
James Caruso
Employees
8
Stock Exchange
NASDAQ
Ticker Symbol
CLRB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for CLRB stock is "Buy." The 12-month stock price forecast is 5.98, which is an increase of 213.09% from the latest price.

Price Target
$5.98
(213.09% upside)
Analyst Consensus: Buy